Printer Friendly

RIBI IMMUNOCHEM ANNOUNCES RESULTS OF ANNUAL MEETING

 HAMILTON, Mont., April 29 /PRNewswire/ -- Accelerated pivotal Phase III human clinical testing of MELACINE(R) melanoma theraccine and accumulation of important data regarding the development of MPL(R) immunomodulator for the prevention of septic shock and cardiac reperfusion injury were among the milestones achieved in 1992 by Ribi ImmunoChem Research Inc. (NASDAQ: RIBI), Robert E. Ivy, chief executive officer, president and chairman, reported yesterday at the company's 12th Annual Meeting of Stockholders.
 "Patient accrual accelerated in the second half of 1992 in the pivotal Phase III study of MELACINE to extend survival in late-stage patients. A pivotal Phase III study of MELACINE to prevent recurrence of melanoma in less-diseased patients who have had primary tumors surgically removed was also initiated. MELACINE is a notable cancer drug since it is rarely associated with untoward side effects and does not interfere with a patient's normal activities," Ivy told stockholders.
 "We anticipate completing patient accrual in the Phase III study in late-stage patients early in the second half of 1993 and, pending successful results, filing a Product License Application with the U.S. Food and Drug Administration in the second half of 1994.
 "We are enthusiastic about the development of MPL immunomodulator to prevent or ameliorate sepsis and septic shock as well as cardiac reperfusion injury, and we have set aggressive development schedules for those programs.
 "The accelerated and expanded product development achieved in 1992 was enabled by an $11-million equity infusion in April 1992. The company finished 1992 with more than $18 million in current assets and long-term investments, which will allow the company to continue its aggressive product development programs," Ivy said.
 During the business session of the Annual Meeting, stockholders re-elected the company's board of directors for the coming year: John L. Cantrell, John F. Chappell, Philipp Gerhardt, Robert E. Ivy, Thomas N. McGowen Jr. and Frederick B. Tossberg.
 Following the stockholders' meeting, the board of directors elected the following officers of the company:
 Robert E. Ivy Chief Executive Officer,
 President and Chairman
 John L. Cantrell, Ph.D. Executive Vice President
 Vern D. Child, C.P.A. Vice President-Finance and
 Treasurer
 Ronald H. Kullick, R.Ph., J.D. Vice President-Legal Counsel and
 Secretary
 Jon A. Rudbach, Ph.D., M.B.A. Vice President-Research and
 Development
 Ribi ImmunoChem Research Inc., a biopharmaceutical company founded in 1981, is a leader in the development of immunostimulants for use in preventing and treating human disease.
 -0- 4/29/93
 /CONTACT: Vern D. Child, vice president-Finance, or Jeffrey S. McDowell, corporate information manager, of Ribi ImmunoChem Research, 406-363-6214/
 (RIBI)


CO: Ribi ImmunoChem Research Inc. ST: Montana IN: MTC SU: PER

LM -- SE002 -- 2497 04/29/93 09:36 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1993
Words:444
Previous Article:RIBI IMMUNOCHEM REPORTS FIRST-QUARTER FINANCIAL RESULTS
Next Article:FORMER USDA DEPUTY SECRETARY JOINS CALGENE FRESH BOARD
Topics:


Related Articles
RIBI IMMUNOCHEM TO EXPAND FACILITY FOR MELACINE PRODUCTION; FACILITY TO EXPAND MELACINE MANUFACTURING CAPACITY 50-FOLD
PROTECTIVE EFFECT OF RIBI'S MPL AGAINST REPERFUSION INJURY DEMONSTRATED IN PRECLINICAL DATA PRESENTED AT ASPET MEETING
RIBI IMMUNOCHEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK
RIBI IMMUNOCHEM WITHDRAWS PUBLIC OFFERING
RIBI IMMUNOCHEM REPORTS FIRST-QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM AND LIDAK PHARMACEUTICALS TO COLLABORATE ON POTENTIAL SECOND-GENERATION THERACCINE TECHNOLOGY
RIBI, AMERICAN CYANAMID COMPLETE CO-EXCLUSIVE ADJUVANT LICENSE/SUPPLY AGREEMENTS
MARK I. GREENE, M.D., PH.D., ELECTED TO RIBI IMMUNOCHEM BOARD OF DIRECTORS
RIBI COMPLETES ADJUVANT LICENSE AGREEMENT FOR NEW SMITHKLINE BEECHAM CANCER VACCINES IN DEVELOPMENT
Ribi ImmunoChem Research, Inc. Presents Corporate Overview at Financial Fest

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters